Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0011854 (
type 1 diabetes
)
20,749
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Interleukin-27
(
IL-27
) is a new member of the IL-12 family. It is produced by activated antigen-presenting cells and plays an important role in the regulation of CD4+ T cell differentiation and immune response.
IL-27
activates multiple signaling cascades, including the JAK-STAT and p38 MAPK pathways. Several studies have revealed that
IL-27
promotes the differentiation of Th1 and Tr1, but inhibits Th2, Th17, and Treg cells. However, a few studies have shown an opposite effect on certain T cell subsets, such as Treg.
IL-27
displays both pro- and anti- inflammatory activities in different autoimmune diseases. Here, we have discussed the role of
IL-27
in rheumatoid arthritis, multiple sclerosis, colitis, lupus, psoriasis,
type 1 diabetes
, and uveitis. Most of this information is derived from experimental models of these autoimmune diseases. The mechanistic basis of the dual role of
IL-27
in inflammation and autoimmunity is still not fully defined. In general, the pro-/anti-inflammatory activity of
IL-27
is influenced by the underlying immune effector pathways, the phase of the disease, the presence or absence of counter-regulatory cytokines/T cell subsets, and the tissue/cell type under study. Despite a spectrum of outcomes in various autoimmune diseases, mostly anti-inflammatory and immunomodulatory effects of
IL-27
have been observed in this category of diseases. Accordingly,
IL-27
represents a novel, promising target/agent for the treatment of autoimmune diseases.
...
PMID:IL-27-induced modulation of autoimmunity and its therapeutic potential. 2625 81
